Pharsight

Drugs that contain Amifampridine Phosphate

1. Firdapse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(10 years from now)

US10626088 CATALYST PHARMS Determining degradation of 3,4-diaminopyridine
Feb, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents